OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director exercised or converted 20K COLL derivative securities | OQRO

Home
Insider trades
Collegium Pharmaceutical, Inc.
Director exercised or converted 20K COLL derivative securities

Insider trades

Insider trade

Director exercised or converted 20K COLL derivative securities

Traded Nov 12, 2025 · Filed Nov 14, 2025

COLCollegium Pharmaceutical, Inc.COLL

20K
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 12, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 14, 2025

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001560152-25-000004

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Nov 14, 2025, 9:10 PM UTC

Added to OQRO

Oct 6, 2026, 10:35 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

COLLEGIUM PHARMACEUTICAL, INC

Issuer CIK

1267565

Ticker

COLL

Reporting person

John A. Fallon

Relationship

Director

Security

Stock Option (Right to Purchase)

Table

Derivative (Table II)

Transaction date

Nov 12, 2025

Transaction code

Shares / units

19,853

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

The option is fully vested and exercisable.

Around the same time

Scott DreyerEVP & Chief Commercial Officer

Filed 10mo ago

18KShares · @ $15.90

Traded Dec 8, 2025 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Scott Dreyer (EVP & Chief Commercial Officer) sold ~$533K of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 10mo ago

Scott Dreyer (EVP & Chief Commercial Officer) sold ~$315K of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 10mo ago